Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05227482
Other study ID # 742/2019/Oss/AOUBo
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 10, 2018
Est. completion date December 31, 2023

Study information

Verified date January 2022
Source IRCCS Azienda Ospedaliero-Universitaria di Bologna
Contact lidia strigari, PhD MSc
Phone 00390512143570
Email lidia.strigari@aosp.bo.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial involves patients with hepatocellular carcinoma (HCC) diagnosis treated with transarterial radioembolization (TARE) with resin microspheres loaded with 90Y. Patients will be divided in two groups based on prescription method to calculate the therapeutic radionuclide activity to be injected. In arm A, standard dosimetric approach such as Body Surface Area (BSA) method and Medical Internal Radiation Dosimetry (MIRD) monocompartmental method will be used. In arm B, novel voxel-based dosimetry, based on pre-treatment simulation with 99m-Technetium (99mTc)-Macro Aggregated Albumin (MAA) injection and SPECT/CT image acquisition, will be used. The primary outcome will be the overall survival of patients included in arm A and arm B. Secondary outcomes will be adverse events, tumor response, biomarkers assessed from blood samples prior and after the treatment and voxel-based dosimetry obtained from post-treatment PET/CT images acquisitions.


Description:

The hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. For a large number of patients surgery is not feasible, due to disease multifocality or liver impairment. Several techniques have been proposed in the last years to treat inoperable HCC, including transarterial radioembolization (TARE), also known as selective internal radiotherapy (SIRT). The TARE is an interventional procedure in which micron-sized embolic particles (resin or glass microspheres) loaded with beta-emitter radionuclides of 90Y are directly injected in the hepatic arteries. This allows to treat the tumor, which receives most of its blood supply from these arteries, and to spare the liver parenchyma, which is supplied mainly by the portal vein. Microparticles are directly released to the target and remain trapped in it, locally delivering a curative amount of radiation dose. In addition to the dose delivered to the tumor and to the liver parenchyma, which have been showed to be related to the treatment efficacy and to the occurrence of liver toxicity, several studies highlighted the role of biomarkers such as the alpha-fetoprotein or the PIVKA-II to describe the tumor progression or aggressiveness. The procedure can be simulated with the injection of 99mTc-labeled macroaggregated albumin (MAA), through the acquisition of a SPECT/CT, and verified after the treatment with bremsstrahlung SPECT imaging or PET imaging. To assess the amount of radionuclide to be injected for a curative purpose (namely, the activity at the injection time), several methods have been proposed. Among them, the Body Surface Area (BSA) method allows to estimate the activity based on patient's height and weight and liver/tumor volumes, while the Medical Internal Radiation Dosimetry (MIRD) monocompartmental method allows to estimate the activity based on the desired dose delivered to the target or liver, assuming that all the activity is deposited inside these volumes. Both methods currently represent the standard dosimetric approach. In addition, in recent years, voxel based dosimetry has been proposed as a novel dosimetric approach. In voxel based dosimetry, the absorbed dose distribution can be calculated from the SPECT/CT acquisition obtained in the simulation procedure prior to the treatment. This allows to take into account the inhomogeneity of the radionuclide distribution among the liver and the target volumes. Voxel based dosimetry can be used to prescribe the activity at injection time that would allow to deliver the desired absorbed dose to the target without exceeding the radiation dose to the healthy tissues. In this randomized trial, patients with hepatocellular carcinoma (HCC) diagnosis are equally divided into arm A (activity prescription based on standard dosimetry approach) and arm B (activity prescription based on novel voxel-based dosimetry approach). The primary goal of the study is to show the superiority of the novel dosimetry approach in terms of patients' overall survival. As secondary goal, the following data will be recorded: adverse events, tumor response, biomarkers assessed from blood samples prior and after the treatment and voxel-based dosimetry obtained from post-treatment PET/CT images acquisitions.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - hepatocellular carcinoma diagnosis (BCLC stage B or C) - appropriate liver function (Child-Pugh A or B<8) - life expectancy > 3 months - bilirubin < 2.0 ng/ml - multidisciplinary team consensus to the treatment - multiphasic CT within 1 month prior to the treatment - written informed consent Exclusion Criteria: - lung shunt fraction > 20% - Child-Pugh score C - BCLC stage D - liver impairment - relevant ascites - hepatic encephalopathy - vascular abnormality not allowing proper catheterization - significant distant metastasis

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Personalized dosimetry approach
The radionuclide activity to administer is calculated using personalized voxel-based dosimetry approach
Standard dosimetry approach
The radionuclide activity to administer is calculated using standard (BSA or MIRD) dosimetry approach

Locations

Country Name City State
Italy IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna

Sponsors (2)

Lead Sponsor Collaborator
IRCCS Azienda Ospedaliero-Universitaria di Bologna Regina Elena Cancer Institute

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival Patients overall survival after receiving the treatment will be recorded. Correlation between the patients survival and the assigned Arm will be assessed. 3 years
Secondary Related adverse events in both arms as assessed by National Cancer Institute criteria (National Cancer Institute Common Terminology Criteria for Adverse Events, CTCAE v.5.0) Related adverse events will be assessed with CTCAE v.5.0. Only adverse events within 6 months from the treatment will be considered treatment-related and considered in the secondary outcome. 6 months
Secondary Tumor response in both arms as assessed by Response Evaluation Criteria in Solid Tumours (RECIST v1.1) Tumor response after the treatment will be assessed with Response Evaluation Criteria in Solid Tumours (RECIST v1.1). 3 years
Secondary Biomarkers prior and after the treatment Biomarkers (PIVKA-II and Alpha-fetoprotein) values will be measured by blood samples prior the treatment (basal value) and at 1-month and 3-months follow-up after the treatment 3 months
Secondary Post-therapeutic dosimetry measured with Positron Emission Tomography - Computed Tomography (PET/CT) acquisition Voxel-based dosimetry will be performed based on a PET/CT acquisition the day after the treatment. The dose delivered to the whole and healthy liver, the tumor and the lungs will be recorded. 1 day
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05458115 - Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
Not yet recruiting NCT05022628 - Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis Phase 4
Enrolling by invitation NCT02256514 - Open Label Trial of Immunotherapy for Advanced Liver Cancer Phase 2
Not yet recruiting NCT06434480 - SBRT in HCC With Oligoprogression on Atezo-Bev N/A
Completed NCT04542837 - The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma Phase 2
Not yet recruiting NCT05025592 - cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
Completed NCT04172506 - A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05840133 - Study of Long Non-coding RNA SNHG15 as a Novel Biomarker in HBV Associated HCC
Not yet recruiting NCT06024252 - Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
Terminated NCT02785874 - Statin With Palliative Therapy for HCC N/A
Not yet recruiting NCT02715492 - Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma. Phase 3
Completed NCT02985034 - Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT N/A
Not yet recruiting NCT06069947 - SALT for Liver Cirrhosis With HCC N/A
Recruiting NCT05581004 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Suspended NCT02935478 - Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation N/A
Recruiting NCT05592171 - Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC N/A
Completed NCT03176485 - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors N/A
Recruiting NCT05544253 - Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC Phase 2/Phase 3
Recruiting NCT06184152 - CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
Completed NCT02675920 - A Study of HCC High Risk Group Using Two Surveillance Tools